Allergy drug could help rheumatoid arthritis patients

NCT ID NCT07632872

Recruiting now Disease control Sponsor: Horus University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether adding desloratadine, an allergy medication, to standard rheumatoid arthritis therapy can reduce joint inflammation and disease activity. Sixty adults with active RA will receive either desloratadine or a placebo for 12 weeks. The study measures changes in disease activity scores and inflammatory markers to see if this common drug offers extra relief.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Desloratadine 5 mg
What this could lead to: If it works, this could point toward a new add-on treatment option for rheumatoid arthritis patients who still have active disease despite standard therapy.
What could go wrong: This is a small, early-phase trial with only 60 participants and a short 12-week follow-up. The results may not be strong enough to change practice, and desloratadine might not provide meaningful benefit over placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Inflammation rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS RHEUMATOID ARTHRITIS (RA)

Contacts and locations

Locations

Faculty of medicine, Mansoura University
RECRUITING

Al Mansurah, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.